October 2013 Editor's Picks: Products from Bosch and One Stop Critical - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

October 2013 Editor's Picks: Products from Bosch and One Stop Critical

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Bosch Packaging Technology
A compact laboratory machine combines drying, granulating, and coating modules.

The Solidlab 2 laboratory device from Hüttlin and Manesty, pharmaceutical process technology suppliers that have been part of Bosch Packaging Technology since 2011, combines several process steps in a compact, modular laboratory machine. Modules for drying, granulating, and coating in the fluid bed, as well as tablet coating in the coater, can be used individually or in combination. The laboratory device includes peripheral systems, such as inlet and exhaust air handling, sensor technology, and a control system.


One Stop Critical
A carrier provides shippers with the ability to move temperature-sensitive freight on dry-van carriers.


CarrierDirect, which provides advisory services to logistics companies and carriers, partnered with One Stop Critical, which manufactures temperature-sensitive shippers and carriers, to launch the Critical Cube, a temperature-controlled carrier that holds a standard-sized pallet and has 77 cubic feet of loadable space. The Critical Cube allows companies to ship less-than-truckload (LTL) temperature-sensitive freight on dry-van carriers, eliminating the need to pay for a dedicated truck or to wait for a consolidated refrigerated-LTL carrier. The Critical Cube uses liquid carbon dioxide to maintain temperatures as low as -30 °F for up to five days. The technology is currently available for intra-California shipments, and will be introduced to other US geographies in late 2013 and early 2014.

.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Equipment and Processing Report,
Click here